Free shipping starts now, no minimum, no coupons required!

FTIDC

A Potent and Selective Antagonist of mGluR1 Receptors

Cat #: F-190
Lyophilized Powder yes
  • Bioassay Tested
  • Source Synthetic
    MW: 358.4
    Purity: >97% (HPLC)
    Effective concentration 1-100 nM.
    Structure
    Chemical name 4-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-N-methyl-N-propan-2-yl-3,6-dihydro-2H-pyridine-1-carboxamide.
    Molecular formula C18H23FN6O.
    CAS No.: 873551-53-2
    PubChem CID 11245287
    Activity FTIDC is a potent and selective allosteric antagonist of the mGluR1 receptor, shown to inhibit L-glutamate-induced Ca2+ mobilization in human and mouse mGluR1a-expressing CHO cells (IC50 values of 5.8 nM and 3.1 nM, respectively), while having a 1000-fold weaker activity against human and rat mGluR5 (IC50 values of 6.2 µM and 9.9 µM, respectively)1.
    References-Activity
    1. Suzuki, G. et al. (2007) J. Pharmacol. Exp. Ther. 321, 1144.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility Up to 100 mM in DMSO. Centrifuge all product preparations before use (10000 x g 5 min).
    Storage of solutions -20°C.
    Our bioassay
    • Alomone Labs FTIDC inhibits mGluR1-mediated Ca2+ mobilization in U2OS cells.
      Alomone Labs FTIDC inhibits mGluR1-mediated Ca2+ mobilization in U2OS cells.
      Dose response of normalized inhibition of human mGluR1 receptors mediated, L-Glutamate evoked Ca2+ mobilization by FTIDC (#F-190). IC50 was determined at 1.45 nM. hmGluR1-expressing cells were loaded with calcium-sensitive dye, incubated with a range of concentrations of FTIDC, and stimulated by 15 µM L-Glutamate (EC80). Changes in intracellular Ca2+ following stimulation were detected as changes in maximum relative fluorescence (RLU) using FLIPRTETRA™.
    References - Scientific background
    1. Suzuki, G. et al. (2007) J. Pharmacol. Exp. Ther. 321,1144.
    2. Satow, A. et al. (2008) J. Pharmacol. Exp. Ther. 326, 577.
    3. Eom, H.S. et al. (2016) PLoS One 11, e0147538.
    Scientific background

    FTIDC is a highly potent and selective allosteric antagonist of mGluR1 receptors and shows very weak potency against human and rat mGluR5 receptors. The inhibition of FTIDC for mGluR1 receptors is shown to be in noncompetitive manner and displays IC50 values of 5.8 and 3.1 nM for human and mouse mGluR1 expressed in CHO cells respectively1.

    Studies using chimeric and mutant mGluR1 show that transmembrane (TM) domains 4 to 7, play an important role in the antagonistic properties of FTIDC. The compound has oral activity on recombinant human, mouse, and rat mGluR1 without species differences in its antagonistic activity. The compound is considered to be a valuable tool for elucidating the functions of mGluR1 in rodents and in humans1,2.

    Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors (GPCR) and play an important role in synaptic plasticity and other neuro-physiological and pathological processes including a major role in central sensitization and neuropathic pain. Type 1 mGluRs are mainly found in somatodendritic domains and postsynaptically regulate neuronal excitability and synaptic transmission through several intracellular second messenger systems2,3.

    Target mGluR1
    Last update: 12/08/2021

    FTIDC (#F-190) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use

    Applications

    Specifications

    Scientific Background

    Shipping and Ordering information